Related Experiment Videos
Phase II evaluation of 4'deoxydoxorubicin in advanced renal cell carcinoma
J A Kish1, J F Ensley, M al-Sarraf
1Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI 48201.
American Journal of Clinical Oncology
|February 1, 1990
Abstract:
4'Deoxydoxorubicin was evaluated in patients with advanced renal carcinoma. Only one partial remission was noted, and no significant cardiac toxicity was seen on serial evaluation of ejection fractions. Appropriate dose escalations were performed.